secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001437749-26-005869
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotechnology Q4 2025 revenue $75.5M, GAAP net income $13.4M; guides FY2026 net income $10-13M
--------------------------------------------------------------------------------

- Q4 2025 product revenue $59.9M (+10% YoY); total revenue $75.5M vs $59.1M YoY including $15.6M royalty.
- GAAP net income Q4 2025 $13.4M ($0.27 basic) vs $19.3M ($0.39) YoY; non-GAAP adjusted net income $15.1M ($0.30).
- Full year 2025 total revenue $228.4M; GAAP net income $31.1M ($0.62) vs $30.3M ($0.62) YoY.
- Cash, equivalents & marketable securities $97.5M; total debt reduced to $22.5M from $67.0M at end of 2024.
- FY2026 guidance: net product revenue $194-198M; total revenue $214-221M; net income $10-13M, excluding valuation allowance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774926005869/0001437749-26-005869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774926005869/pbyi20260204_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-005869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer